证券代码：000881 证券简称：中广核技 公告编号：2023-079 中广核核技术发展股份有限公司 第十届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、董事会会议召开情况 1、中广核核技术发展股份有限公司（以下简称"公司"、"上市公司"或"中广 核技"）第十届董事会第九次会议（以下简称"本次会议"）通知于 2023 年 8 月 14 日以电子邮件形式发出。 2、本次会议于 2023 年 8 月 24 日上午 9:00 时在深圳市福田区深南大道 2002 号中广核大厦北楼 19 层 881 会议室以现场会议的方式召开。 3、本次会议应出席董事 9 名，实际现场出席会议董事 9 名。 4、本次会议由董事长李勇先生召集并主持。公司 3 名监事、董事会秘书及 部分高管人员列席会议。 5、本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 二、董事会会议审议情况 经出席会议的董事审议和表决，本次会议形成以下决议，独立董事对相关议 案已发表事前认可和同意的独立意见。 （一）审议通过《关于调整本次交易 ...

中广核核技术发展股份有限公司 《合规管理制度》修订对照表 | 序号 | 原文 | | 修订后 | | --- | --- | --- | --- | | 1 | 目录 | | 目录 | | | 第一章 | 总则 | 第一章 总则 | | | 第二章 | 管理原则 | 第二章 组织和职责 | | | 第三章 | 合规管理组织体系及职责 | 第三章 制度建设 | | | 第四章 | 合规管理运行 | 第四章 运行机制 | | | 第五章 | 合规管理保障 | 第五章 合规文化 | | | 第六章 | 合规报告 | 第六章 信息化建设 | | | 第七章 | 附则 | 第七章 监督问责 | | | | | 第八章 附则 | | 2 | 第一条 为推动中广核核技术发展股 | | 第一条 为深入贯彻习近平法治思想，落实全 | | | 份有限公司（后文简称"中广核技" | | 面依法治国战略部署，推动公司加强合规管 | | | 或"公司"）及其控股子公司和托管 | | 理，切实防控风险，保障深化改革与高质量 | | | 公司（两者合称"子公司"）全面加 | | 发展，依据《中华人民共和国公司法》《中 | | | 强合规管 ...

证券代码：000881 证券简称：中广核技 公告编号：2023-070 中广核核技术发展股份有限公司 关于召开 2023 年半年度业绩说明会并征集相关 问题的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 中广核核技术发展股份有限公司（以下简称"公司"）定于 2023 年 8 月 26 日披露公司《2023 年半年度报告》。为进一步加强与广大投资者的沟通交流，公 司计划召开 2023 年半年度业绩说明会，现将有关事项公告如下： 一、说明会类型 本次业绩说明会将以网络文字交流的形式召开，公司将主要围绕 2023 年半 年度业绩及经营情况与投资者进行交流，在信息披露允许的范围内答复投资者普 遍关注的问题。 党委书记、董事长李勇，党委副书记、董事、总经理盛国福，独立董事孙光 国，总会计师杨凌浩，党委委员、董事会秘书杨新春。 五、问题征集 为更好地服务投资者，保证业绩说明会活动规范有序，投资者可于 2023 年 8 月 29 日（星期二）下午 17:30 前将相关问题发送至下述联系邮箱。 六、联系方式 二、召开时间 2023 年 8 月 30 日（星期三）15 ...

证券代码：000881 证券简称：中广核技 中广核核技术发展股份有限公司投资者关系活动记录表 编号：2023-002 | 投资者关系活动 | 特定对象调研 分析师会议 | | --- | --- | | 类别 | 媒体采访 业绩说明会 | | | 新闻发布会  路演活动 | | | 现场参观 其他 | | 外部参与人员 | 申万宏源、中金公司、中信银行、鹏华基金、博时基金、南方基 | | | 金、安信证券等机构分析师和投资者，合计约 45 人 | | 上市公司参与人 | 党委委员、董事会秘书杨新春 | | 员 | | | 活动时间 | 2023 年 5 月 11 日 14:30-16:30 | | 活动地点 | 深圳大中华希尔顿酒店 | | 活动形式 | 现场会议 | | 记录 | 年 月 日，公司参加了实际控制人旗下上市公司集 2023 5 11 | | | 体路演活动。活动中，公司董事会秘书杨新春介绍了公司核心业 | | | 务概况及上一会计年度经营情况和亮点，并与参会者就关注问题 | | | 进行交流，相关问答如下： | | | 1.公司业务比较多元？未来是否会聚焦在某个行业领域？ | ...

证券代码：000881 证券简称：中广核技 中广核核技术发展股份有限公司投资者关系活动记录表 编号：2023-001 | 投资者关 | 特定对象调研 分析师会议 | | | | | --- | --- | --- | --- | --- | | 系活动类 | 媒体采访 | 业绩说明会  | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 | 其他 | | | | 参与单位 | 招商证券 | 胡小禹 | 天风证券 | 李东烨 | | 名称及人 | 招商证券 | 朱艺晴 | 上海乘舟投资 | 刘晓波 | | 员姓名 | 国信证券 | 年亚颂 | 安信证券 | 朱睿泽 | | | 中信证券 | 杜松阳 | 山西证券 | 徐风 | | | 德邦证券 | 许蕾 | 东方财富证券 | 钟志坤 | | | 德邦证券 | 蔡萌萌 | 东亚前海证券 | 曲文慧 | | | 中邮证券 | 虞洁攀 | 东亚前海证券 | 王丽丽 | | | 个人投资者 | 李雄 | 煜德投资 | 管俊玮 | | | 恒大人寿保险 | 魏大千 | 财通证券 | 赵璐 | | | 九九资本 | 葛大维 | 金 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥1,226,257,155.66, a decrease of 37.58% compared to ¥1,964,657,949.31 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥25,735,870.78, representing a decline of 167.55% from a profit of ¥38,099,280.83 in the previous year[5] - The company reported a significant decrease in sales revenue from trade business, contributing to the overall decline in operating revenue[11] - Total operating revenue for Q1 2023 was CNY 1,226,257,155.66, a decrease of 37.6% compared to CNY 1,964,657,949.31 in the same period last year[22] - Net profit for Q1 2023 was a loss of CNY 22,072,604.24, compared to a profit of CNY 66,936,584.05 in Q1 2022, representing a significant decline[23] - The total comprehensive income for Q1 2023 was a loss of CNY 29,206,761.51, compared to a gain of CNY 62,832,936.35 in Q1 2022[23] Cash Flow - The net cash flow from operating activities improved to ¥10,676,777.73, a 117.44% increase from a negative cash flow of ¥61,231,440.33 in the same period last year[5] - Cash received from operating activities increased by 60.67% to ¥370,079,088.33, indicating improved cash inflow from trade business[12] - The cash inflow from operating activities was CNY 1,625,927,347.96, a decrease of 27.2% compared to CNY 2,232,869,505.59 in the previous period[24] - The cash outflow for investing activities totaled CNY 387,408,075.99, down from CNY 467,668,152.33 in the previous period[25] - The cash inflow from financing activities was CNY 441,303,232.73, a decrease of 41.5% from CNY 754,072,607.59 in the previous period[25] - The company received CNY 17,405,913.81 in tax refunds, an increase from CNY 10,755,846.98 in the previous period[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥11,520,697,514.16, down 3.77% from ¥11,972,423,061.82 at the end of the previous year[5] - Total liabilities decreased to CNY 4,801,257,606.33 from CNY 5,230,703,000.11, a decline of 8.2%[22] - As of March 31, 2023, the total current assets amounted to CNY 6,726,017,707.56, a decrease of 6.54% from CNY 7,197,108,305.49 at the beginning of the year[19] - The cash and cash equivalents decreased to CNY 1,427,055,059.79 from CNY 1,604,278,600.79, reflecting a decline of 11.06%[19] - The company's non-current assets totaled CNY 2,433,880,052.16, a decrease from CNY 2,453,296,316.40 at the beginning of the year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 38,927, with the largest shareholder holding 27.28% of the shares[14] - The company completed the initial grant of stock options under the 2022 equity incentive plan, totaling 25.96 million options at an exercise price of CNY 7.33 per option[16] Strategic Initiatives - The company is in the process of acquiring 100% equity of Beigu Technology through a combination of share issuance and cash payment, with ongoing audits and asset evaluations[17] - The company is actively pursuing market expansion and strategic acquisitions to enhance its competitive position in the industry[17] Research and Development - Research and development expenses for Q1 2023 were CNY 37,975,849.50, down 20.5% from CNY 47,778,528.01 in the previous year[22] Governance - The company has completed the election of the 10th Board of Directors and Supervisory Board, along with the appointment of senior management personnel during the reporting period[18] Other Financial Metrics - The weighted average return on equity decreased to -0.41%, down 1.03 percentage points from 0.62% in the previous year[5] - The company reported a basic and diluted earnings per share of -0.0272 for Q1 2023, compared to 0.0403 in the same period last year[23] - The company's goodwill remained stable at CNY 421,600,099.03, unchanged from the previous quarter[22]

Financial Performance - The company's operating revenue for 2022 was ¥6,944,907,174.49, a decrease of 13.18% compared to ¥7,998,857,682.91 in 2021[18]. - The net profit attributable to shareholders increased by 12.46% to ¥198,751,228.01 in 2022 from ¥176,723,237.79 in 2021[18]. - The net profit after deducting non-recurring gains and losses was negative at -¥67,036,499.95, a decline of 225.75% compared to ¥53,309,874.16 in 2021[18]. - The cash flow from operating activities increased by 18.48% to ¥563,624,947.09 in 2022 from ¥475,720,066.83 in 2021[18]. - The total assets at the end of 2022 were ¥11,972,423,061.82, a decrease of 10.13% from ¥13,322,236,426.35 at the end of 2021[18]. - The company achieved a weighted average return on equity of 3.20% in 2022, an increase of 0.27 percentage points from 2.93% in 2021[18]. - The company's total revenue for 2022 was approximately CNY 6.94 billion, a decrease of 13.63% compared to the previous year[90]. - The gross profit margin for the new materials segment was 10.45%, down 2.46% year-on-year[90]. - The revenue from overseas operations was CNY 756.86 million, representing a 51.20% increase compared to the previous year[90]. Business Strategy and Development - The company completed a major asset restructuring, expanding its main business to include electronic accelerator research and manufacturing, radiation processing, and medical health services[15]. - The company has established a new strategy focusing on market expansion and technological innovation in nuclear technology applications[15]. - The company is focusing on the development of electronic accelerators, with key technology breakthroughs achieved in 2022, enhancing performance and efficiency[30]. - The company plans to integrate research, production, and application services in the electronic accelerator industry to meet the growing demand in various sectors[30]. - The company aims to enhance brand recognition and market promotion while increasing R&D investment to gain a technological advantage[34]. - The company is actively expanding its market presence with new product developments and strategic investments in irradiation technology and medical isotopes[76]. Research and Development - The company has established 15 irradiation centers and operates 60 electron accelerators, positioning itself as a leader in electron beam irradiation processing in China[75]. - The company has a total of 493 authorized patents, including 240 invention patents, indicating strong R&D capabilities[75]. - Research and development expenses for 2022 were ¥343,632,316.47, an increase of 7.85% compared to ¥318,615,066.97 in 2021[105]. - The company's R&D investment as a percentage of operating revenue rose to 4.95%, up from 3.98% in the previous year[105]. - The number of R&D personnel increased by 12.77% to 627 in 2022, compared to 556 in 2021[104]. Market Outlook and Trends - The domestic irradiation sterilization market is projected to reach a potential market space of approximately 5.5 billion RMB, with the irradiation modification industry expected to reach around 30 billion RMB[37]. - The global modified plastics market is expected to grow at a rate of around 3%, with demand projected to reach 130 million tons by 2026[39]. - The global proton therapy equipment market is still in its early development stage, with North America being the largest market and the Asia-Pacific region expected to grow the fastest due to increasing demand for advanced cancer treatment[44]. - The company is accelerating the promotion of proton therapy equipment while initiating the development of small proton therapy equipment to strengthen its core competitiveness in the nuclear medicine field[47]. Governance and Management - The company emphasizes strict compliance with fundraising management regulations, focusing on efficiency and cost-effectiveness in project implementation[129]. - The company has established a comprehensive governance structure, ensuring clear responsibilities and effective checks and balances among its decision-making bodies[154]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, and operations[157]. - The company experienced significant management changes in 2022, with multiple executives resigning due to work adjustments, including the resignation of the Chief Financial Officer on January 17, 2022[175]. - The company appointed a new Chief Financial Officer on the same day, indicating a swift transition in leadership[176]. Challenges and Risks - The company emphasizes the importance of risk awareness regarding forward-looking statements in the annual report, highlighting potential risks and countermeasures[3]. - The company reported a loss of CNY 29,393,150.05 in asset impairment, accounting for 7.00% of total profit, mainly due to inventory write-downs and goodwill impairment[111]. - The company has faced challenges in achieving planned progress and expected returns due to fluctuations in raw material prices and market supply-demand imbalances[135]. - The company aims to strengthen risk management and ensure stable business development in 2023[71]. Future Projections - The company provided a positive outlook for 2023, projecting a revenue growth of 12% to 15%, aiming for a target of 11.2 billion RMB[182]. - The company plans to enhance the production equipment level of squid fishing vessels in 2023 to improve operational efficiency and output value[69]. - The company aims to achieve a new accelerator order volume not lower than the 2022 level and improve the average output value of equipment by over 10%[144]. - The company plans to invest approximately 1 billion yuan in the proton project, with construction of the production facility ongoing[77].

一、活动时间 2023 年 4 月 27 日（星期四）下午 15:30—17:00。 二、活动方式 证券代码：000881 证券简称：中广核技 公告编号：2023-032 中广核核技术发展股份有限公司 关于举行 2022 年度业绩说明会并征集相关问题的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 中广核核技术发展股份有限公司（以下简称"公司"或"中广核技"）将于 2023 年 4 月 27 日披露公司《2022 年年度报告》。为让广大投资者进一步了解公 司 2022 年度经营及业绩情况，公司定于 2023 年 4 月 27 日（星期四）下午 15:30 —17:00 举办 2022 年度业绩说明会。 本次年度业绩说明会将采用现场交流的方式举行，欢迎广大投资者积极参 与。现将有关事项公告如下： 党委书记、董事长胡冬明，党委副书记、董事、总经理盛国福，独立董事孙 光国或康晓岳，党委委员、总会计师谭剑锋，党委委员、董事会秘书杨新春。 四、问题征集 为更好地服务投资者，投资者可于 2023 年 4 月 27 日（星期四）中午 11:00 前将相关问题通过电 ...

Group 1: Company Overview - China General Nuclear Power Technology Development Co., Ltd. is a leading supplier of industrial electron accelerators, with over 200 units produced and sold domestically, and 18 units sold internationally, achieving a domestic market share of over 70% in the export of industrial electron accelerators [3][4]. Group 2: Business Segments - The company operates the largest electron accelerator irradiation processing service in China, with 9 irradiation processing centers and 41 accelerators in operation, totaling a power of 3700 kW [3][4]. - Approximately 50% of medical devices globally utilize radiation sterilization, while only about 10% of medical devices in China use this method, indicating significant growth potential in the domestic market [4]. Group 3: Technological Advancements - The company has developed electronic accelerators for radiation curing, with the global market for radiation curing production lines growing at a rate of 12% annually, reaching over 800 lines by 2007 [5][6]. - The company has successfully developed electronic accelerators for tire pre-sulfurization, with a market space estimated at around 1 billion yuan [5][6]. Group 4: Market Potential - The domestic cable material market is estimated to be between 600-800 billion yuan, while the engineering plastics market is around 1 trillion yuan, with an industry growth rate of approximately 7% [7]. - The company aims to enter the biomedical polymer materials sector, targeting high-end markets for artificial bones and blood vessels, as well as mid-range medical devices [7].

Group 1: Company Performance and Strategy - In 2019, the company introduced the "A+ strategy" to strengthen accelerator manufacturing and expand accelerator application scenarios [2][3] - The company reported a goodwill impairment of approximately 28 million in 2019, primarily due to traditional businesses affected by market cycles [4] - The net asset scale of the original Dalian International business is less than 1 billion, with low profitability [4] Group 2: Market Position and Competition - The company's market share in modified polymer materials is among the top in the domestic market, with plans to enhance revenue and gross margin through technological innovation and support from China General Nuclear Power Group [3][4] - The nuclear technology application business includes accelerator manufacturing, irradiation applications, and modified polymer materials, with no direct domestic competitors in the accelerator and irradiation sectors [3] Group 3: Future Outlook and Key Areas - The company aims to focus on industrial applications, including irradiation materials and disinfection, as well as nuclear medicine and public safety [3][4] - The estimated market size for nuclear technology applications in China is approximately 2 trillion to 3 trillion, based on the ratio of nuclear technology application value to GDP in developed countries [4]